Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company based in New York, focused on developing novel treatments for brain health disorders, including MM-120 for anxiety and ADHD, and MM-402 for autism. Founded in 2015, the company employs 57 people and targets neurotransmitter pathways using psychedelics and empathogens.
Mind Medicine (MNMD) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Mind Medicine's actual EPS was -$0.27, beating the estimate of -$0.29 per share, resulting in a 5.46% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
